Arvinas (ARVN) stock faces a downgrade after underwhelming trial data for breast cancer drug vepdegestrant developed with ...
Arvinas stock plummets 53% on mixed data from phase III metastatic breast cancer study on lead pipeline candidate, vepdegestrant.
Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus ...
Arvinas shares plunged 45% after its Pfizer-partnered breast cancer drug, vepdegestrant, failed to delay cancer progression for all patients. The drug only met its goal for a subset of patients with a ...
A local breast cancer survivor is hoping to break down barriers when it comes to increasing diversity in medical trials.
Mixed clinical results led shares of Arvinas Inc. (NASDAQ:ARVN) to close March 11 at $8.30, down $9.26, or 52%, after the company and Pfizer Inc. disclosed results from the phase III Veritac-2 study ...
Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.
Investor's Business Daily on MSN22h
Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer DrugArvinas stock lost half its value Tuesday after the biotech company reported mixed results from its Pfizer-partnered breast ...
VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...
ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback